Northwestern University researchers discovered that rearranging components in an HPV cancer vaccine can dramatically improve its effectiveness. By repositioning a small protein fragment on their spherical DNA nanovaccine, they created a version that slowed tumor growth, extended survival in animal models, and generated far more cancer-killing T cells than other configurations using identical ingredients. This finding demonstrates that vaccine structure matters as much as ingredients, opening new possibilities for optimizing cancer immunotherapies through precise molecular arrangement rather than adding new components.
